(1999). Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation
Decision Making in Health and Medicine: Integrating evidence and values.
Derivation, validation, and evaluation of a new QRISK model to estimate lifetime risk of cardiovascular disease: cohort study using QResearch database.
Differences between coronary disease and stroke in incidence, case fatality, and risk factors, but few differences in risk factors for fatal and non-fatal events. Eur Heart J 2005;26:1916e22. ADDIN RW.BIB.
(1993). Discounting in the economic evaluation of health care interventions. Med Care
(2011). JBS Rip Up Rules Cardiovascular Risk.
(1993). Markov models in medical decision making: a practical guide. Med Decis Making
(1988). Medical Decision Making.
(2001). Myocardial Infarction: An Investigation Of Measures Of Mortality, Incidence And Case-Fatality. Report to the Department of Health.
Norway’s new principles for primary prevention of cardiovascular disease: age differentiated risk thresholds.
(2007). Ofﬁce for National Statistics. Deaths by age, sex and underlying cause,
(2009). Ofﬁce for National Statistics. Interim Life Tables 2005-2007.
(2008). Ofﬁce for National Statistics. Population Estimates for UK, England and Wales, Scotland and Northern Ireland (Table 3)dCurrent Datasets
Optimal age for starting lipid lowering treatment. It is more efﬁcient to screen and treat elderly people.
(1998). Prediction of coronary heart disease using risk factor categories. Circulation
(2006). Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. Circulation
(2008). Quantifying the effect of age on short-term and long-term case fatality in 14,000 patients with incident cases of cardiovascular disease.
(2005). Should age and time be eliminated from cardiovascular risk prediction models? Rationale for the creation of a new national risk detection program. Circulation
The inﬂuence of absolute cardiovascular risk, patient utilities, and costs on the decision to treat hypertension: a Markov decision analysis.
(2005). Treatment with drugs to lower blood pressure and blood cholesterol based on an individual’s absolute cardiovascular risk. Lancet